Eupraxia Pharmaceuticals (EPRX) AI Stock Analysis

• Market Cap: C$608.90M
• Dividend Yield: N/A
• Average Volume (3M): 53.43K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.76
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: CA
• Employees: 33
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.27
• Shares Outstanding: 50,648,330
• 10 Day Avg. Volume: 45,847
• 30 Day Avg. Volume: 53,430
• PEG Ratio: 0.09
• Price to Book (P/B): 3.18
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -3.53
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: C$18.09
• Price Target Upside: 52.14% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 4
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 52 Neutral
• Price Target: C$10.50 ▼(-11.69% Downside)

The score is held back primarily by weak financial performance (no revenue, sizable losses, and persistent cash burn), partially offset by a stronger balance sheet with low leverage. Technicals are supportive with a strong uptrend, but overbought momentum raises pullback risk. Valuation remains constrained due to negative earnings and no dividend support.

Positive Factors

Operational Progress

The advancements in the RESOLVE trial demonstrate Eupraxia's capability to progress its drug pipeline, potentially leading to future product commercialization and revenue generation.

Capital Raise

The capital raise enhances Eupraxia's liquidity, providing the necessary funds to continue operations and advance clinical trials, reducing immediate financial risk.

Positive Trial Results

Promising trial results for EP-104GI indicate potential for successful treatment options, which could lead to regulatory approvals and market entry, strengthening the company's competitive position.

Negative Factors

Financial Instability

The lack of revenue and persistent net losses highlight financial instability, which could hinder long-term sustainability and limit the ability to fund ongoing operations without external financing.

Cash Flow Challenges

Negative cash flows indicate reliance on external funding, posing risks to operational continuity and financial flexibility, potentially affecting the company's ability to invest in growth opportunities.

High Liabilities

High liabilities can strain financial resources and limit strategic options, potentially affecting the company's ability to respond to market changes or invest in new projects.

Eupraxia Pharmaceuticals Business Overview & Revenue Model

Company Description

Eupraxia Pharmaceuticals Inc., a clinical stage biotechnology company, engages in the discovery, development, and marketing of technologies in the biotechnology sector. The company's lead product candidate is EP-104IAR, which is in a Phase II clinical trial for the treatment of unmet medical needs and for pain relief for knee osteoarthritis, as well as under development for treating canine and equine osteoarthritis. Its products in development also include EP-201, an antibiotic for post-surgical site infections; and EP-105, an extended-release post-surgical anesthetic for post-surgical pain. In addition, the company develops product candidates for oncology. The company was formerly known as Plaza Capital Partners Inc. and changed its name to Eupraxia Pharmaceuticals Inc. in May 2012.Eupraxia Pharmaceuticals Inc. was incorporated in 2011 and is headquartered in Victoria, Canada.

How the Company Makes Money

Eupraxia Pharmaceuticals primarily generates revenue through the development and potential commercialization of its drug candidates. The company is focused on advancing its lead product candidates through clinical trials, seeking regulatory approval, and ultimately bringing these products to market. Revenue is expected to be derived from product sales, licensing agreements, and strategic partnerships. Eupraxia may engage in collaborations with larger pharmaceutical companies to co-develop or commercialize its products, thus gaining access to additional resources and market channels. However, as a clinical-stage company, Eupraxia's current revenue is likely limited and largely dependent on funding from investors, grants, or milestone payments from partnerships until its products receive regulatory approval and can be commercialized.

Eupraxia Pharmaceuticals Financial Statement Overview

Summary

Eupraxia Pharmaceuticals faces significant financial challenges, marked by zero revenue and ongoing net losses. Despite a strong cash position, reliance on external financing and persistent cash burn due to negative operating cash flows indicate financial instability.

Income Statement

Eupraxia Pharmaceuticals has recorded consistent negative revenue growth with no reported revenue over the years, resulting in substantial net losses. Gross profit and EBIT margins are negative, indicating significant operating challenges without revenue generation.

Balance Sheet

The company maintains a strong cash position relative to its liabilities, evidenced by a high equity ratio. However, the debt-to-equity ratio is skewed by negative equity in past years, and high liabilities pose a risk, despite recent improvements in stockholders' equity.

Cash Flow

Persistent negative operating and free cash flows highlight liquidity challenges. Cash flow from financing has been the main source of liquidity, indicating reliance on external funding. Free cash flow growth remains negative, suggesting ongoing cash burn.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00	0.00
Gross Profit	-219.64K	-235.25K	-209.91K	-193.27K	-111.53K	-116.81K
EBITDA	-31.61M	-33.72M	-37.40M	-22.14M	-21.96M	-2.01M
Net Income	-35.15M	-34.94M	-37.39M	-23.26M	-22.99M	-4.00M
Balance Sheet
Total Assets	128.50M	50.24M	26.72M	25.88M	31.22M	1.45M
Cash, Cash Equivalents and Short-Term Investments	123.78M	33.10M	19.34M	24.74M	29.90M	150.13K
Total Debt	237.38K	103.31K	10.45M	10.55M	9.49M	12.77M
Total Liabilities	5.43M	4.46M	25.55M	14.51M	11.67M	23.12M
Stockholders Equity	125.27M	33.40M	2.22M	12.86M	20.39M	-21.21M
Cash Flow
Free Cash Flow	-25.24M	-30.10M	-28.02M	-19.08M	-15.07M	-403.93K
Operating Cash Flow	-24.80M	-29.99M	-27.92M	-18.78M	-14.64M	-403.93K
Investing Cash Flow	-439.40K	-75.16K	-99.03K	8.70M	-14.45M	24.62K
Financing Cash Flow	106.30M	45.78M	27.84M	13.52M	49.92M	-626.64K

Eupraxia Pharmaceuticals Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 11.89
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Negative
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:EPRX, the sentiment is Positive. The current price of 11.89 is above the 20-day moving average (MA) of 9.63, above the 50-day MA of 8.95, and above the 200-day MA of 7.16, indicating a bullish trend. The MACD of 0.62 indicates Negative momentum. The RSI at 75.83 is Negative, neither overbought nor oversold. The STOCH value of 74.89 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:EPRX.

Eupraxia Pharmaceuticals Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
NGEN	53 Neutral	C$643.12M	-22.35	-790.82%	―	―	2.22%
DRUG	53 Neutral	C$932.51M	-69.57	-30.79%	―	―	-43.64%
EPRX	52 Neutral	C$608.90M	-9.79	-59.46%	―	―	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
FRX	46 Neutral	C$346.86M	-30.57	―	―	-19.08%	-451.99%
MDNA	44 Neutral	C$64.60M	-5.54	-91.21%	―	―	54.74%
ARCH	26 Underperform	C$83.96M	-34.60	―	―	―	10.49%

Eupraxia Pharmaceuticals Corporate Events

Eupraxia Posts Strong Mid-Stage Data for Once-Yearly EoE Therapy EP-104GI

Eupraxia Pharmaceuticals reported encouraging interim results from the Phase 1b/2a portion of its RESOLVE trial of EP-104GI in eosinophilic esophagitis, showing near-complete normalization of esophageal tissue health at the highest dose by week 12 and sustained improvements at lower doses out to week 36. A majority of patients who had at least 60% of their esophagus treated achieved and maintained clinical remission for up to 52 weeks after a single administration, with more than 200 patient-months of follow-up showing no serious adverse events or oral candidiasis, bolstering EP-104GI’s profile as a potentially once-yearly treatment and supporting ongoing recruitment in the randomized Phase 2b trial, with top-line data expected in 2026.

The most recent analyst rating on (TSE:EPRX) stock is a Buy with a C$16.00 price target. To see the full list of analyst forecasts on Eupraxia Pharmaceuticals stock, see the TSE:EPRX Stock Forecast page.